# Kidney Transplantation

## Definition & Classification

**Kidney Transplantation**: A surgical procedure to place a healthy kidney from a donor into a person whose kidneys no longer function properly. This is the preferred treatment for most patients with end-stage renal disease (ESRD).

### Types of Kidney Transplants

**By Donor Source**:
- **Living Donor Transplant**:
  - **Living Related Donor (LRD)**: Blood relative (sibling, parent, child)
  - **Living Unrelated Donor (LURD)**: Spouse, friend, or altruistic donor
  - **Paired Kidney Exchange**: Donor-recipient pairs exchange kidneys for better compatibility
- **Deceased Donor Transplant**:
  - **Standard Criteria Donor (SCD)**: Typical deceased donor
  - **Expanded Criteria Donor (ECD)**: Older or less-ideal donors
  - **Donation after Cardiac Death (DCD)**: Donation after circulatory death
  - **Donation after Brain Death (DBD)**: Traditional deceased donation

**By Transplant Number**:
- **First Transplant**: Initial kidney transplant
- **Re-transplantation**: Subsequent transplant after failure of previous graft

**By HLA Matching**:
- **Zero-Antigen Mismatch**: Perfect HLA match (rare outside identical twins)
- **Partial Match**: Some HLA compatibility
- **Poor Match**: Minimal HLA compatibility, higher immunosuppression needs

**By Pre-transplant Dialysis Status**:
- **Pre-emptive Transplant**: Transplant before initiating dialysis
- **Post-Dialysis Transplant**: Transplant after period on dialysis

### Post-Transplant Phases

- **Immediate Post-Transplant**: 0-3 months after surgery
- **Early Post-Transplant**: 3-12 months after surgery
- **Maintenance Phase**: Beyond 12 months after surgery
- **Long-term Phase**: Beyond 5 years after surgery

## Required Evidence

### Minimum Documentation

1. **Transplant details**:
   - Date of transplantation
   - Transplant center
   - Donor type (living vs. deceased)
   - Original cause of kidney failure
   - Pre-transplant dialysis duration (if applicable)
   - HLA matching information (if available)
   - Previous transplants (if any)

2. **Current graft function**:
   - Recent serum creatinine and eGFR values
   - Trend of renal function over time (stable, improving, declining)
   - Presence of proteinuria
   - Blood pressure control
   - Most recent urine analysis

3. **Rejection history**:
   - Episodes of acute rejection
   - Treatment for rejection
   - Outcomes of rejection episodes
   - Kidney biopsy results (if performed)
   - Evidence of chronic rejection

4. **Immunosuppression regimen**:
   - Current medications and dosages
   - Therapeutic drug levels
   - Changes in regimen
   - Side effects or complications
   - Compliance with immunosuppression

5. **Complications assessment**:
   - Infection history (particularly opportunistic infections)
   - Cardiovascular status
   - Malignancy screening
   - Bone disease
   - New onset diabetes after transplant (NODAT)
   - Metabolic complications

### Additional Evidence for Complex Cases

- Detailed transplant nephrologist consultation notes
- Complete hospitalization records for complications
- Kidney biopsy reports
- DSA (donor-specific antibody) testing results
- Cardiovascular evaluation results
- Cancer screening results
- Special testing for viral infections (BK virus, CMV, etc.)

## Rating Guidelines

### Kidney Transplant from Living Donor

| Post-Transplant Duration | Graft Function | Rating |
|------------------------|---------------|--------|
| <1 year | Any | Postpone |
| 1-3 years | Excellent (eGFR >60, Cr <1.5) | Table 5-7 |
| 1-3 years | Good (eGFR 45-60, Cr 1.5-2.0) | Table 6-8 |
| 1-3 years | Fair (eGFR 30-44, Cr 2.1-3.0) | Table 7-9 |
| 3-5 years | Excellent (eGFR >60, Cr <1.5) | Table 4-6 |
| 3-5 years | Good (eGFR 45-60, Cr 1.5-2.0) | Table 5-7 |
| 3-5 years | Fair (eGFR 30-44, Cr 2.1-3.0) | Table 6-8 |
| >5 years | Excellent (eGFR >60, Cr <1.5) | Table 3-5 |
| >5 years | Good (eGFR 45-60, Cr 1.5-2.0) | Table 4-6 |
| >5 years | Fair (eGFR 30-44, Cr 2.1-3.0) | Table 5-7 |
| Any duration | Poor (eGFR <30, Cr >3.0) | Postpone or Decline |

**Modifying Factors**:
- Pre-emptive transplantation: -1 table
- Zero HLA mismatch: -1 table
- No rejection episodes: -1 table
- History of acute rejection resolved: +1 table
- Proteinuria >500 mg/day: +1 table
- Proteinuria >1 g/day: +2 tables
- Excellent compliance documented: -1 table
- Sibling donor: -1 table

### Kidney Transplant from Deceased Donor

| Post-Transplant Duration | Graft Function | Rating |
|------------------------|---------------|--------|
| <1 year | Any | Postpone |
| 1-3 years | Excellent (eGFR >60, Cr <1.5) | Table 6-8 |
| 1-3 years | Good (eGFR 45-60, Cr 1.5-2.0) | Table 7-9 |
| 1-3 years | Fair (eGFR 30-44, Cr 2.1-3.0) | Table 8+ or Postpone |
| 3-5 years | Excellent (eGFR >60, Cr <1.5) | Table 5-7 |
| 3-5 years | Good (eGFR 45-60, Cr 1.5-2.0) | Table 6-8 |
| 3-5 years | Fair (eGFR 30-44, Cr 2.1-3.0) | Table 7-9 |
| >5 years | Excellent (eGFR >60, Cr <1.5) | Table 4-6 |
| >5 years | Good (eGFR 45-60, Cr 1.5-2.0) | Table 5-7 |
| >5 years | Fair (eGFR 30-44, Cr 2.1-3.0) | Table 6-8 |
| Any duration | Poor (eGFR <30, Cr >3.0) | Postpone or Decline |

**Modifying Factors**:
- Standard criteria donor: No adjustment
- Expanded criteria donor: +1 table
- Donation after cardiac death: +1 table
- No rejection episodes: -1 table
- History of acute rejection resolved: +1 table
- Delayed graft function with recovery: +1 table
- Proteinuria >500 mg/day: +1 table
- Proteinuria >1 g/day: +2 tables
- Excellent compliance documented: -1 table

### Re-transplantation (Second or Subsequent Transplant)

| Post-Transplant Duration | Graft Function | Rating |
|------------------------|---------------|--------|
| <2 years | Any | Postpone |
| 2-5 years | Excellent (eGFR >60) | Table 7-9 |
| 2-5 years | Good (eGFR 45-60) | Table 8+ |
| >5 years | Excellent (eGFR >60) | Table 6-8 |
| >5 years | Good (eGFR 45-60) | Table 7-9 |
| Any duration | Fair or Poor (eGFR <45) | Postpone or Decline |

**Modifying Factors**:
- First graft survived >5 years: -1 table
- First graft lost due to recurrent disease: +1 table
- First graft lost due to non-compliance: +2 tables
- Living donor for re-transplant: -1 table
- Multiple prior transplants: +2 tables

### ABO-Incompatible or Positive Crossmatch Transplant

| Post-Transplant Duration | Graft Function | Rating |
|------------------------|---------------|--------|
| <3 years | Any | Add 1 table to standard transplant rating |
| 3-5 years | Excellent/Good | Add 1 table to standard transplant rating |
| >5 years | Excellent/Good | Same as standard transplant rating |
| Any duration | Fair/Poor | Postpone or Decline |

**Modifying Factors**:
- Stable low antibody titers: -1 table
- Rising antibody titers: +1 table
- Special desensitization protocol: No additional rating

## Postpone/Decline Criteria

### Postpone

1. Recent transplant (<12 months)
2. Recent acute rejection episode (<6 months)
3. Significant decline in renal function under investigation
4. Recent adjustment to immunosuppression regimen (<3 months)
5. Recent significant infection (<3 months)
6. New onset proteinuria under investigation
7. BK virus nephropathy under treatment
8. Pending biopsy or invasive procedure
9. Newly diagnosed post-transplant malignancy under treatment

### Decline

1. Severe chronic allograft nephropathy
2. Graft failure requiring return to dialysis
3. Active rejection not responding to treatment
4. eGFR consistently <30 ml/min with declining trend
5. Recurrent primary disease with significant allograft dysfunction
6. Severe BK virus nephropathy not responding to treatment
7. Multiple serious infections due to immunosuppression
8. Advanced transplant coronary artery disease
9. Post-transplant lymphoproliferative disorder (PTLD) or active malignancy
10. Documented non-compliance with immunosuppressive medications

## Medication Considerations

| Medication Category | Examples | Underwriting Significance |
|--------------------|----------|---------------------------|
| **Calcineurin Inhibitors** | Tacrolimus (Prograf), Cyclosporine (Neoral) | Primary immunosuppressants; level stability important; can cause nephrotoxicity |
| **Antimetabolites** | Mycophenolate (CellCept), Azathioprine (Imuran) | Common adjunctive agents; mycophenolate preferred in modern regimens |
| **mTOR Inhibitors** | Sirolimus (Rapamune), Everolimus (Zortress) | May be used for CNI-sparing protocols or patients with malignancy history |
| **Corticosteroids** | Prednisone | Dose is significant; steroid-free protocols may have fewer metabolic complications |
| **Belatacept** | Nulojix | Newer biologic agent; may indicate CNI intolerance |
| **Other Immunosuppressants** | Alemtuzumab, Anti-thymocyte globulin | Induction agents; not relevant to long-term risk |
| **Antihypertensives** | ACE inhibitors, ARBs, Calcium channel blockers | Blood pressure control important; ACE/ARBs may protect against proteinuria |
| **Prophylactic Antimicrobials** | Valganciclovir, Trimethoprim-Sulfa | Indicate infection prevention; generally favorable |

## Comorbidity Factors

The following conditions may increase kidney transplant ratings:

| Comorbidity | Rating Adjustment |
|-------------|-------------------|
| Diabetes mellitus (pre-existing) | +1 to 2 tables |
| New onset diabetes after transplant | +1 table |
| Hypertension (poorly controlled) | +1 to 2 tables |
| Coronary artery disease | +2 to 3 tables |
| Recurrent infections | +1 to 2 tables |
| Hepatitis B or C | +1 to 3 tables |
| HIV infection (well-controlled) | +2 tables |
| Significant obesity | +1 table |
| History of malignancy | +2 to 4 tables depending on type/recency |
| Osteoporosis | +1 table |
| Hyperparathyroidism | +1 table |
| Chronic viral infection (e.g., CMV, BK) | +1 to 2 tables |

## Improvement Factors

Ratings may be improved with:

1. **Graft function stability**:
   - Longer duration post-transplant with stable function
   - Consistently excellent kidney function (eGFR >60)
   - No proteinuria
   - No evidence of chronic allograft nephropathy
   - Normal biopsies (if performed)

2. **Immunosuppression management**:
   - Stable medication regimen
   - Therapeutic drug levels without toxicity
   - Reduced immunosuppression over time without complications
   - Minimal side effects from medications
   - Steroid-free protocol success

3. **Complication-free course**:
   - No rejection episodes
   - No significant infections
   - Absence of de novo donor-specific antibodies
   - Well-controlled blood pressure
   - No post-transplant malignancies
   - Normal cardiovascular screening

4. **Compliance and follow-up**:
   - Perfect medication adherence
   - Regular attendance at follow-up appointments
   - Adherence to lifestyle recommendations
   - Strong support system
   - Patient education and understanding

## Special Considerations

### Pediatric Kidney Transplant Recipients Now Adults

| Current Age | Years Post-Transplant | Graft Function | Rating |
|-------------|----------------------|----------------|--------|
| 18-30 | >10 years | Excellent | Reduce base rating by 1 table |
| 18-30 | >10 years | Good | Standard base rating |
| 18-30 | <10 years | Any | Standard base rating |
| >30 | >15 years | Excellent | Reduce base rating by 1-2 tables |
| >30 | >15 years | Good | Reduce base rating by 0-1 table |
| >30 | <15 years | Any | Standard base rating |

**Modifying Factors**:
- Growth and development issues: +1 table
- Transition issues to adult care: +1 table
- Medication adherence issues: +1 to 2 tables
- Normal growth and development: -1 table

### Recurrent Primary Disease Risk

| Original Disease | Recurrence Status | Rating |
|-----------------|------------------|--------|
| **Focal Segmental Glomerulosclerosis** | No recurrence >3 years | Standard transplant rating |
| **Focal Segmental Glomerulosclerosis** | Recurrence with treatment response | Add 1 table to base rating |
| **Focal Segmental Glomerulosclerosis** | Recurrence without response | Add 2 tables or Postpone |
| **IgA Nephropathy** | No recurrence >5 years | Standard transplant rating |
| **IgA Nephropathy** | Recurrence without dysfunction | Add 1 table to base rating |
| **Diabetic Nephropathy** | Recurrence | Add 1 table to base rating |
| **ANCA-associated Vasculitis** | No recurrence >5 years | Standard transplant rating |
| **ANCA-associated Vasculitis** | Recurrence | Add 2 tables to base rating |
| **Anti-GBM Disease** | No recurrence >5 years | Standard transplant rating |
| **Membranous Nephropathy** | Recurrence | Add 1 table to base rating |

### Kidney-Pancreas Transplantation

| Post-Transplant Duration | Function Status | Rating |
|------------------------|----------------|--------|
| <2 years | Any | Postpone |
| 2-5 years | Both organs functioning well | Kidney transplant rating + 1 table |
| 2-5 years | Kidney functioning, pancreas failure | Kidney transplant rating + 1 table |
| >5 years | Both organs functioning well | Kidney transplant rating + 0-1 table |
| >5 years | Kidney functioning, pancreas failure | Kidney transplant rating |
| Any duration | Kidney dysfunction | See Kidney Transplant guidelines |

**Modifying Factors**:
- Insulin independence: -1 table
- Recurrent diabetic nephropathy: +1 table
- Type 1 vs. Type 2 diabetes: No difference if controlled
- Simultaneous vs. sequential transplant: -1 table for simultaneous

### Post-Transplant Pregnancy

| Timing of Pregnancy | Outcome | Current Status | Rating |
|--------------------|---------|--------------|--------|
| <2 years post-transplant | Any | Stable graft function | Add 1 table to base rating |
| >2 years post-transplant | Uncomplicated | Stable graft function | Standard transplant rating |
| >2 years post-transplant | Complicated | Returned to baseline | Add 1 table to base rating |
| >2 years post-transplant | Complicated | Persistent dysfunction | Add 2 tables or Individual consideration |
| Any timing | Multiple pregnancies | Stable function | Standard transplant rating |

**Modifying Factors**:
- Pre-eclampsia: +1 table for 1 year
- Rejection during pregnancy: +2 tables
- Need for medication adjustments: +1 table
- Return to baseline function post-delivery: -1 table

### Transplant Coronary Artery Disease / Cardiovascular Risk

| Severity | Management | Rating |
|----------|-----------|--------|
| **Mild CAD** | Medical management | Add 1 table to base rating |
| **Moderate CAD** | Successful intervention | Add 2 tables to base rating |
| **Severe CAD** | Multiple interventions | Add 3 tables or Individual consideration |
| **Multiple risk factors** | Well-controlled | Add 1 table to base rating |
| **Previous cardiac event** | >1 year ago, stable | Add 2 tables to base rating |
| **Previous cardiac event** | <1 year ago | Postpone |

## References

1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Guidelines
2. American Society of Transplantation Guidelines
3. Scientific Registry of Transplant Recipients (SRTR) Data
4. United Network for Organ Sharing (UNOS) Guidelines
5. Society of Actuaries Mortality Studies related to kidney transplantation